Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial

Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial

ObjectiveThe mechanisms that explain the cardio-renal benefits of sodium glucose co-transporter 2 (SGLT-2) inhibitors are unknown. The effect of SGLT-2 inhibitors on arterial aging, measured by Aortic Pulse Wave Velocity (Ao-PWV) and Soluble Klotho (s-Klotho), a circulating anti-aging biomarker of a...

Full description

Bibliographic Details
Main Authors: Janaka Karalliedde, Nikos Fountoulakis, Dimitra Stathi, Antonella Corcillo, Maria Flaquer, Angeliki Panagiotou, Giuseppe Maltese, Anastasios Mangelis, Salma Ayis, Luigi Gnudi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
diabetic kidney disease
arterial stiffness
albuminuria
arterial aging
SGLT-2 inhibitors
Klotho
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.992327/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.992327/full

Similar Items